TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Immutep Ltd ( (AU:IMM) ) has issued an announcement.
Immutep Ltd’s recent presentation at their Annual General Meeting 2025 provided an update on the company’s business activities. The presentation emphasized the company’s ongoing efforts and strategic plans, although it included forward-looking statements subject to various risks and uncertainties. Stakeholders are advised to consider these factors carefully, as actual results may differ from current expectations.
The most recent analyst rating on (AU:IMM) stock is a Hold with a A$0.25 price target. To see the full list of analyst forecasts on Immutep Ltd stock, see the AU:IMM Stock Forecast page.
More about Immutep Ltd
Immutep Ltd operates in the biotechnology industry, focusing on empowering the immune system to combat cancer and autoimmune diseases. The company is listed on ASX and NASDAQ under the symbols IMM and IMMP, respectively.
Average Trading Volume: 2,185,450
Technical Sentiment Signal: Sell
Current Market Cap: A$390.1M
See more insights into IMM stock on TipRanks’ Stock Analysis page.